Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA(®)) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced the grant of non-statutory stock options to two newly hired employees.

Korro granted the new employees nonstatutory stock options to purchase 4,000 shares of Korro’s common stock, in the aggregate, at an exercise price of $8.88 per share, the closing price per share of Korro's common stock as reported by Nasdaq on the grant effective date, October 14, 2026. The options each have a ten-year term and vest over four years, with 25% of the shares vesting on the first anniversary of each such employee’s applicable start date and the remaining 75% vesting in 36 equal monthly installments on each monthly anniversary thereafter until the fourth anniversary of such employee’s applicable start date, subject to the employee’s continued service with Korro through each applicable vesting date.